RE: Today4 Aug 2022 14:22
Sept 2016
"Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI)."
I have asked Mitchell twice if anyone at Sareum has had the nous to enter into dialogue with CRT to ascertain if they have been in contact with GSK about the 737 licence but, of course, no response. I believe mention was made of some form of contact in this morning's "presentation" but nothing more.
For Mitchell to say they have no influence in the matter is utter rubbish. They are "co-investment partners" with one of the signatories to the Licence are they not?
I may have it all wrong of course in which case somebody will enlighten me perhaps?